KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Net Income: 2009-2025

Historic Net Income for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $432.0 million.

  • Teva Pharmaceutical Industries' Net Income rose 209.92% to $432.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $658.0 million, marking a year-over-year increase of 125.84%. This contributed to the annual value of -$2.0 billion for FY2024, which is 217.67% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Net Income stood at $432.0 million for Q3 2025, which was up 53.74% from $281.0 million recorded in Q2 2025.
  • Teva Pharmaceutical Industries' 5-year Net Income high stood at $519.0 million for Q1 2024, and its period low was -$1.8 billion during Q4 2023.
  • Moreover, its 3-year median value for Net Income was -$253.0 million (2023), whereas its average is -$270.2 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 1,286.59% in 2022, then surged by 305.14% in 2024.
  • Teva Pharmaceutical Industries' Net Income (Quarterly) stood at -$151.0 million in 2021, then slumped by 783.44% to -$1.3 billion in 2022, then slumped by 34.63% to -$1.8 billion in 2023, then spiked by 84.69% to -$275.0 million in 2024, then surged by 209.92% to $432.0 million in 2025.
  • Its Net Income was $432.0 million in Q3 2025, compared to $281.0 million in Q2 2025 and $220.0 million in Q1 2025.